Florquinitau F 18 Environmental Risk Assessment (ERA) report
Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
Not verified
Molecular formula
Not verified
Molecular weight
Not verified g/mol
Drug class
Tau-targeted fluorine-18 radiopharmaceuticaldiagnostic PET imaging agent
Mechanism of action
Binds to aggregated tau protein in the brain, including tau neurofibrillary tangles. After intravenous administration it crosses the blood-brain barrier and accumulates in regions containing tau aggregates; fluorine-18 positron emissions permit PET visualisation.
Indications / reported uses
PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to identify patients with tau neurofibrillary-tangle pathology, under the US TAUKLARIFY product indication.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Florquinitau F 18 Environmental Risk Assessment (ERA) (the Florquinitau F 18 ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.